查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
充血性心臟衰竭药物市场，按类型、药物类别、分销管道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1351452

充血性心臟衰竭药物市场，按类型、药物类别、分销管道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Congestive Heart Failure Drugs Market, By Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 297 Pages | 商品交期: 2-3个工作天内

价格

报告要点

充血性心臟衰竭药物 2022 年市场规模为 66.009 亿美元，2023 年至 2030 年复合年增长率为 15.8%。

充血性心臟衰竭药物市场-市场动态：

  • 老年人口的增加以及高血压、肥胖和糖尿病发病率的增加预计将促进行业成长。
  • 老年人有更多的合併症，并且经常服用多种药物，使他们更容易受到药物交互作用和加剧心臟衰竭的影响。肥胖也与其他健康问题有关，例如睡眠呼吸中止症和糖尿病，这两者都会增加心臟衰竭的风险。根据世界卫生组织的数据，2020 年有3,900 万5 岁以下儿童超重或肥胖。随着新兴经济体医疗保健基础设施的发展，对现代医疗治疗的需求日益增长，特别是治疗慢性心臟衰竭等疾病的药物，提供了成长机会为市场。然而，先进的治疗方法，如心臟再同步治疗 (CRT) 和其他医疗设备有时可以减少对药物的需求。

充血性心臟衰竭药物市场 - 主要见解：

  • 根据我们的研究分析师分享的分析，全球充血性心臟衰竭药物市场预计在预测期内（2023-2030）每年将以 15.8% 左右的复合年增长率成长
  • 由于人们对永续成长的认识不断增强，充血性心臟衰竭药物产业预计将以显着的速度成长
  • 根据类型细分，预计左心衰竭将在 2022 年呈现最大市场份额
  • 根据药物类别细分，血管张力素 II 受体阻断剂（ARB）是 2022 年的主导类型
  • 从分销通路细分来看，2022年医院药局是主导类型
  • 按地区划分，北美是 2022 年的主要收入来源

充血性心臟衰竭药物市场-細項分析：

  • 全球充血性心臟衰竭药物市场根据类型、药物类别、分销管道和地区进行细分。
  • 市场依类型分为三类：左侧心臟衰竭、右侧心臟衰竭和高输出量心臟衰竭。左侧心臟衰竭较常见，又进一步细分为射血分数降低型心臟衰竭（HFrEF）和射血分数维持型心臟衰竭（HFpEF）。
  • 依药物类别，市场分为两类：ACE抑制剂、血管张力素2受体阻断剂、β受体阻断剂、利尿剂、醛固酮拮抗剂、正性肌力药物等。血管张力素 2 受体阻断剂在市场上占据主导地位，并可能在预测期内保持其主导地位。血管张力素 II 受体阻断剂 (ARB) 是一类重要的药物，用于治疗各种心血管疾病，包括充血性心臟衰竭 (CHF)，特别是无法耐受 ACE 抑制剂的患者。
  • 根据分销管道，市场分为两类：医院药房、零售药房和线上药房。医院药房产业占据市场主导地位。医院药局对于各种疾病（包括充血性心臟衰竭（CHF））的药物分配和配药至关重要。

充血性心臟衰竭药物市场-地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。由于医疗支出激增、对心臟健康的高度认识以及医疗保健服务可用性的增加，预计北美将推动充血性心臟衰竭药物市场的成长。美国是世界上人均医疗费用最高的国家之一。这笔巨额支出不可避免地增加了获得药物和治疗的机会。根据医疗保险和医疗补助服务中心的数据，2021 年美国医疗保健支出将增加 2.7%，达到 4.3 兆美元，即人均 12,914 美元。医疗支出占国内生产毛额的比重为18.3%。由于研发活动支出的增加，欧洲成为该市场成长的第二大地区。

充血性心臟衰竭药物市场-竞争格局：

充血性心臟衰竭 (CHF) 药物市场有各种各样的参与者，从老牌製药巨头到专注于尖端疗法的新进者。虽然几家着名的製药公司正在开发治疗慢性心臟衰竭的新疗法，但仿製药也有很大的市场，特别是因为许多早期的慢性心臟衰竭治疗方法的专利已经到期。 CHF 药品市场已经发生了大量的併购，较大的企业收购较小的公司或与较小的公司合作，将新的治疗方法引入其产品线。例如，2023年3月6日，默沙东（在美国和加拿大以外地区称为MSD）宣布，美国食品药物管理局（FDA）已批准可溶性鸟苷酸环化酶（sGC）刺激剂VERQUVO，用于降低心血管疾病风险有症状的慢性心臟衰竭且射血分数低于 45% 的成人因心臟衰竭住院或需要门诊静脉注射 (IV) 利尿剂后死亡和心臟衰竭住院。

最近的发展：

2023 年3 月1 日，安进公司（NASDAQ：AMGN）宣布新的Repatha (evolocumab) 结合了3 期FOURIER 和FOURIER 开放标籤扩展(OLE) 研究以及在研olpasiran 的2 期OCEAN( a)-DOSE 研究资料。siRNA 可将脂蛋白 (a) [Lp(a)] 降低 90% 以上。

目录

第一章：充血性心臟衰竭药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按类型分類的充血性心臟衰竭药物市场片段
    • 按药物类别分類的充血性心臟衰竭药物市场片段
    • 按分销管道分類的充血性心臟衰竭药物市场片段
    • 按国家/地区分類的充血性心臟衰竭药物市场片段
    • 按地区分類的充血性心臟衰竭药物市场片段
  • 竞争洞察

第 3 章：充血性心臟衰竭药物主要市场趋势

  • 充血性心臟衰竭药物市场驱动因素
    • 市场驱动因素的影响分析
  • 充血性心臟衰竭药物市场限制
    • 市场限制影响分析
  • 充血性心臟衰竭药物市场机会
  • 充血性心臟衰竭药物市场未来趋势

第 4 章：充血性心臟衰竭药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：充血性心臟衰竭药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：充血性心臟衰竭药物市场格局

  • 2022 年充血性心臟衰竭药物市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：充血性心臟衰竭药物市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 左心衰竭
    • 右心衰竭
    • 高输出量心臟衰竭

第 8 章：充血性心臟衰竭药物市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • ACE抑制剂
    • 血管张力素 2 受体阻断剂
    • β受体阻断剂
    • 利尿剂
    • 醛固酮拮抗剂
    • 正性肌力药
    • 其他的

第 9 章：充血性心臟衰竭药物市场 - 按分销管道

  • 概述
    • 按分销管道分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：充血性心臟衰竭药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 充血性心臟衰竭药物北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按分销管道）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲充血性心臟衰竭药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按分销管道）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区充血性心臟衰竭药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模和预测（按分销管道）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲充血性心臟衰竭药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模和预测（按分销管道）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 充血性心臟衰竭药物是中东和非洲的主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按分销管道）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 充血性心臟衰竭药品产业

  • 竞争仪表板
  • 公司简介
    • Bayer AG
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson & Johnson Services, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Novo Nordisk A/S

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1694

REPORT HIGHLIGHT

Congestive heart failure drugs Market size was valued at USD 6,600.9 Million in 2022, expanding at a CAGR of 15.8% from 2023 to 2030.

Congestive heart failure (CHF) is a complex clinical illness caused by any anatomical or functional cardiac problem that inhibits the heart's ability to fill with or pump enough blood throughout the body. The most effective therapy for CHF is generally determined by the underlying cause of the heart failure, its severity, and any other medical disorders the patient may have. The goal of treatment for chronic congestive heart failure (CHF) is to enhance symptom management and quality of life, reduce hospitalizations, and lower overall mortality.

Congestive heart failure drugs Market - Market Dynamics:

  • A rise in the geriatric population and an increase in the incidence of hypertension, obesity, and diabetes are expected to augment industry growth.
  • Elderly people have more comorbid diseases and frequently take many drugs, making them more vulnerable to drug interactions and conditions that exacerbate heart failure. Obesity is also linked to other health issues such as sleep apnea and diabetes, both of which raise the risk of heart failure. According to the World Health Organization, 39 million children under the age of 5 were overweight or obese in 2020. As rising economies' healthcare infrastructure develops, there is an increasing need for modern medical treatments, especially medications for illnesses such as CHF providing growth opportunities for the market. However, Advanced treatments such as cardiac resynchronization therapy (CRT) and other medical devices can occasionally reduce the need for pharmaceuticals.

Congestive heart failure drugs Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Congestive heart failure drugs market is estimated to grow annually at a CAGR of around 15.8% over the forecast period (2023-2030)
  • The Congestive heart failure drugs industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on type segmentation, Left-sided Heart Failure was predicted to show maximum market share in the year 2022
  • Based on drug class segmentation, Angiotensin II Receptor Blockers (ARBs were the leading type in 2022
  • Based on distribution channel segmentation, hospital Pharmacies were the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Congestive Heart Failure Drugs Market- Segmentation Analysis:

  • The Global Congestive Heart Failure Drugs Market is segmented on the basis of Type, Drug Class, Distribution Channel, and Region.
  • The market is divided into three categories based on type: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure. Left-sided heart failure is more prevalent, and it is further subdivided into heart failures with reduced ejection fraction (HFrEF) and heart failures with maintained ejection fraction (HFpEF).
  • The market is divided into two categories based on Drug Class: ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others. The Angiotensin 2 Receptor Blockers dominate the market and are likely to maintain their dominance during the forecast period. Angiotensin II Receptor Blockers (ARBs) are an essential class of drugs used to treat a variety of cardiovascular disorders, including congestive heart failure (CHF), particularly in patients who cannot tolerate ACE inhibitors.
  • The market is divided into two categories based on Distribution Channels: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital Pharmacies sector dominates the market. Hospital pharmacies are essential in the distribution and dispensing of medications for a variety of diseases, including congestive heart failure (CHF).

Congestive heart failure drugs Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to drive the growth of the Congestive Heart Failure Drugs Market, due to a Surge in medical spending, high awareness about cardiac health, and an increase in the availability of healthcare services. The United States has one of the world's largest per capita healthcare expenses. This significant expenditure inevitably increases access to medications and therapies. According to the Center for Medicare and Medicaid Service, U.S. healthcare spending will grow 2.7 percent in 2021, reaching USD 4.3 trillion or USD 12,914 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 18.3 percent. Europe held the second largest region for the growth of this market, due to a rise in spending on research & development activities.

Congestive heart failure drugs Market- Competitive Landscape:

The market for congestive heart failure (CHF) medications has seen a variety of participants, ranging from established pharmaceutical behemoths to newer entrants focused on cutting-edge therapy. While several prominent pharmaceutical companies are developing novel treatments for CHF, there is also a substantial market for generic medications, especially because many of the earlier CHF treatments have had their patents expire. The CHF medicine market has seen a sufficient number of mergers and acquisitions, with larger players acquiring or collaborating with smaller companies to bring novel treatments into their pipelines. For Example, on 6 march 2023, Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.

Recent Developments:

On March 1, 2023, Amgen (NASDAQ: AMGN) announced new Repatha (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, a siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET KEY PLAYERS

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY TYPE

  • Left-sided Heart Failure
  • Right-sided Heart Failure
  • High-output Heart Failure

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DRUG CLASS

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Congestive Heart Failure Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Congestive Heart Failure Drugs Market Snippet by Type
    • 2.1.2. Congestive Heart Failure Drugs Market Snippet by Drug Class
    • 2.1.3. Congestive Heart Failure Drugs Market Snippet by Distribution Channel
    • 2.1.4. Congestive Heart Failure Drugs Market Snippet by Country
    • 2.1.5. Congestive Heart Failure Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Congestive Heart Failure Drugs Key Market Trends

  • 3.1. Congestive Heart Failure Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Congestive Heart Failure Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Congestive Heart Failure Drugs Market Opportunities
  • 3.4. Congestive Heart Failure Drugs Market Future Trends

4. Congestive Heart Failure Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Congestive Heart Failure Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Congestive Heart Failure Drugs Market Landscape

  • 6.1. Congestive Heart Failure Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Congestive Heart Failure Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Left-sided Heart Failure
    • 7.1.3. Right-sided Heart Failure
    • 7.1.4. High-output Heart Failure

8. Congestive Heart Failure Drugs Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 8.1.2. ACE Inhibitors
    • 8.1.3. Angiotensin 2 Receptor Blockers
    • 8.1.4. Beta Blockers
    • 8.1.5. Diuretics
    • 8.1.6. Aldosterone Antagonists
    • 8.1.7. Inotropes
    • 8.1.8. Others

9. Congestive Heart Failure Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Congestive Heart Failure Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Congestive Heart Failure Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Congestive Heart Failure Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Congestive Heart Failure Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Congestive Heart Failure Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Congestive Heart Failure Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Congestive Heart Failure Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Bayer AG
    • 11.2.2. Novartis AG
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. AstraZeneca
    • 11.2.5. Bristol-Myers Squibb Company
    • 11.2.6. Amgen Inc.
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. Pfizer, Inc.
    • 11.2.9. Johnson & Johnson Services, Inc.
    • 11.2.10. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.11. Eli Lilly and Company
    • 11.2.12. Novo Nordisk A/S

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Congestive Heart Failure Drugs Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Congestive Heart Failure Drugs Market, by Type 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Congestive Heart Failure Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Congestive Heart Failure Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Congestive Heart Failure Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)